Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals

Djaïleb, Abdelhadi; Jodaylami, Maryam Hojjat; Coutu, Julien; Ricard, Pierre; Lamarre, Mathieu; Rochet, Léa N. C.; Cellier-Goetghebeur, Stella; Macaulay, Devin; Charron, Benjamin; Lavallée, Étienne; Thibault, Vincent; Stevenson, Kristen E.; Forest, Simon; Live, Ludovic S.; Abonnenc, Nanouk; Guedon, Anthony; Quessy, Patrik; Lemay, Jean-François; Farnós, Omar; Kamen, Amine; Stuible, Matthew; Gervais, Christian; Durocher, Yves; Cholette, François; Mesa, Christine; Kim, John; Cayer, Marie-Pierre; Grandmont, Marie-Joëlle De; Brouard, Danny; Trottier, Sylvie; Boudreau, Denis; Pelletier, Joelle N.; Masson, Jean-François

doi:10.1039/d1an00893e

Cited by 33 publications

(45 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the international level, similar studies describing COVID-19 immunoassays have been reported from several research groups [ 29 , 30 , 31 , 32 , 33 , 34 ]. Most of these immunoassays were based on SARS-CoV-2 full-length S, NP, or fragments of S (e.g., receptor binding domain).…”

Section: Development Of Serological Assays For Covid-19supporting

confidence: 53%

“…In some cases, assays were optimized not only for detection of IgM and IgG, but also for IgA [ 33 ]. Validation of results was also evaluated against RT-PCR, the MN assay, and commercially available kits [ 29 , 30 , 31 , 32 , 33 , 34 ]. Herein, we review several in-house immunoassays developed in Saudi Arabia.…”

Section: Development Of Serological Assays For Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi Arabia

Alandijany

Faizo

2021

Healthcare

View full text Add to dashboard Cite

Serological assays are valuable tools for tracking COVID-19 spread, estimation of herd immunity, and evaluation of vaccine effectiveness. Several reports from Saudi Arabia describe optimized in-house protocols that enable detection of SARS-CoV-2 specific antibodies and measurement of their neutralizing activity. Notably, there were variations in the approaches utilized to develop and validate these immunoassays in term of sample size, validation methodologies, and statistical analyses. The developed enzyme-linked immunoassays (ELISAs) were based on the viral full-length spike (S), S1 subunit, and nucleocapsid (NP), and enabled detection of IgM and/or IgG. ELISAs were evaluated and validated against a microneutralization assay utilizing a local SARS-CoV-2 clinical isolate, FDA-approved commercially available immunoassays, and/or real-time polymerase chain reaction (RT-PCR). Overall, the performance of the described assays was high, reaching up to 100% sensitivity and 98.9% specificity with no cross-reactivity with other coronaviruses. In-house immunoassays, along with commercially available kits, were subsequently applied in a number of sero-epidemiological studies aiming to estimate sero-positivity status among local populations including healthcare workers, COVID-19 patients, non-COVID-19 patients, and healthy blood donors. The reported seroprevalence rates differed widely among these studies, ranging from 0.00% to 32.2%. These variations are probably due to study period, targeted population, sample size, and performance of the immunoassays utilized. Indeed, lack of sero-positive cases were reported among healthy blood donors during the lockdown, while the highest rates were reported when the number of COVID-19 cases peaked in the country, particularly among healthcare workers working in referral hospitals and quarantine sites. In this review, we aim to (1) provide a critical discussion about the developed in-house immunoassays, and (2) summarize key findings of the sero-epidemiological studies and highlight strengths and weaknesses of each study.

show abstract

Section: Development Of Serological Assays For Covid-19supporting

confidence: 53%

Section: Development Of Serological Assays For Covid-19mentioning

confidence: 99%

Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi Arabia

Alandijany

Faizo

2021

Healthcare

View full text Add to dashboard Cite

show abstract

“… 93 Protein‐based detection of COVID‐19 is not limited to manual ELISA. Digital ELISA, CLIA, surface plasmon resonance (SPR), 94 flow cytometry, 95 lateral flow immunoassay (LFIA), 96 and microfiber‐based immunoassay 97 are other protein‐based tests, which have been used or are in progress for the diagnosis of SARS‐CoV‐2. Digital ELISA, also called a single‐molecule array (Simoa), is a technique whose sensitivity is in the femtomolar range.…”

Section: Detectionmentioning

confidence: 99%

COVID‐19: A systematic review and update on prevention, diagnosis, and treatment

Aliabadi

Eivazzadeh‐Keihan

Parikhani

et al. 2022

MedComm

View full text Add to dashboard Cite

Since the rapid onset of the COVID‐19 or SARS‐CoV‐2 pandemic in the world in 2019, extensive studies have been conducted to unveil the behavior and emission pattern of the virus in order to determine the best ways to diagnosis of virus and thereof formulate effective drugs or vaccines to combat the disease. The emergence of novel diagnostic and therapeutic techniques considering the multiplicity of reports from one side and contradictions in assessments from the other side necessitates instantaneous updates on the progress of clinical investigations. There is also growing public anxiety from time to time mutation of COVID‐19, as reflected in considerable mortality and transmission, respectively, from delta and Omicron variants. We comprehensively review and summarize different aspects of prevention, diagnosis, and treatment of COVID‐19. First, biological characteristics of COVID‐19 were explained from diagnosis standpoint. Thereafter, the preclinical animal models of COVID‐19 were discussed to frame the symptoms and clinical effects of COVID‐19 from patient to patient with treatment strategies and in‐silico/computational biology. Finally, the opportunities and challenges of nanoscience/nanotechnology in identification, diagnosis, and treatment of COVID‐19 were discussed. This review covers almost all SARS‐CoV‐2‐related topics extensively to deepen the understanding of the latest achievements (last updated on January 11, 2022).

show abstract

“…The in-house and commercial ELISAs were then used to undertake multi-site validation, which demonstrated good cross-correlations with Pearson's coefficients surpassing 0.85 in all cases for detection plasma and DBS. In the context of viral infection and vaccination effectiveness monitoring, this method paves the door for point-of-care and fast antibody testing [105].…”

Section: Immunoassaymentioning

confidence: 99%

A review on corona virus disease 2019 (COVID-19): current progress, clinical features and bioanalytical diagnostic methods

2022

View full text Add to dashboard Cite

A new epidemic of acute respiratory viral pneumonia was discovered in central China at the end of 2019. The disease was given the name coronavirus disease 2019 (COVID-19), and the virus that caused this disease was known as severe acute respiratory syndrome coronavirus (SARS-CoV-2). So far, diagnostic methods have been focused on (a) human antibody detection, (b) viral antigen detection and (c) viral gene detection, the latter using RT-PCR being the most accurate approach. In this paper, we present a summary of the COVID-19 pandemic, clinical features and epidemiology and pathogenesis. Also, we focus on the recent advances in bioanalytical diagnostic methods based on various techniques for SARS-CoV-2 sensing that have recently been published (2020)(2021). Furthermore, we present the mechanisms, advantages and disadvantages of the most common biosensors for COVID-19 detection, which include optical, electrochemical and piezoelectric biosensors as well as wearable and smart nanobiosensors, immunosensors, aptasensors and genosensors.

show abstract

Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals

Abstract: We report on the development of surface plasmon resonance (SPR) sensors and matching ELISAs for the detection of nucleocapsid and spike antibodies specific against the novel coronavirus 2019 (SARS-CoV-2) in...

Cited by 33 publications

References 58 publications

Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi Arabia

Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi Arabia

COVID‐19: A systematic review and update on prevention, diagnosis, and treatment

A review on corona virus disease 2019 (COVID-19): current progress, clinical features and bioanalytical diagnostic methods

Contact Info

Product

Resources

About